Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development
| Autor: | Huiling Li, Sumana R Chintalapudi, Monica M. Jablonski |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Drug Pathology medicine.medical_specialty genetic structures media_common.quotation_subject Degeneration (medical) Bioinformatics 03 medical and health sciences Atrophic age-related macular degeneration Macular Degeneration 0302 clinical medicine Geographic Atrophy medicine Market potential Animals Humans Pharmacology (medical) Molecular Targeted Therapy Pathological media_common Aged Pharmacology Inflammation business.industry General Medicine Drugs Investigational Macular degeneration medicine.disease eye diseases Geographic atrophy Clinical trial Oxidative Stress 030104 developmental biology Drug Design 030221 ophthalmology & optometry business |
| Zdroj: | Expert opinion on investigational drugs. 26(10) |
| ISSN: | 1744-7658 |
| Popis: | Age-related macular degeneration (AMD) is the leading cause of vision loss among the elderly. Atrophic AMD, including early, intermediate and geographic atrophy (GA), accounts for ~90% of all cases. It is a multifactorial degeneration characterized by chronic inflammation, oxidative stress and aging components. Although no FDA-approved treatment yet exists for the late stage of atrophic AMD, multiple pathological mechanisms are partially known and several promising therapies are in various stages of development. Areas covered: Underlying mechanisms that define atrophic AMD will help provide novel therapeutic targets that will address this largely unmet clinical need. The purpose of this paper is to review current promising drugs that are being evaluated in clinical trials. Because no pharmacological treatments are currently available for late stage of atrophic AMD, any new therapy would have extensive market potential. Expert opinion: The number of AMD patients is predicted to increase to ~30 million worldwide by 2020. In response to this enormous unmet clinical need, new promising therapies are being developed and evaluated in clinical trials. We propose that the assessment of novel interventions will also need to consider the genotypes of participants, as the benefit may be determined by polymorphisms in an individual's genetic background. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|